Find Academic Supervisors

• Cardiovascular Medicine
• Medical Imaging
• Coronary Artery Disease
• +3 more

Rafail Kotronias serves as a Clinical Research Fellow at the Division of Cardiovascular Medicine, University of Oxford, and is affiliated with Exeter College. He is an active member of the Antoniades Group: The Oxford Translational Cardiovascular Research Group, specializing in advanced cardiovascular imaging and interventional techniques. His research focuses on developing novel photon-counting detector computed tomography for non-invasive coronary and myocardial phenotyping. Leveraging expertise in multimodal imaging and intervention, Kotronias aims to advance personalized cardiovascular medicine through integration of cutting-edge imaging within hybrid multidisciplinary centers for trialing innovative pharmacological and device therapies in coronary disease patients. His work bridges invasive and non-invasive coronary assessment methodologies to improve patient risk stratification and treatment. Recent publications (2024-2025) demonstrate concentrated efforts in photon-counting CT technology for coronary stenosis assessment, myocardial characterization, and inflammation imaging. His research extends to interventional cardiology innovations including stent-retriever thrombectomy for STEMI and hybrid approaches to coronary microvascular resistance assessment, while maintaining interdisciplinary connections through analytical chemistry applications in plasma biomarker research. His contributions have been recognized through prestigious funding support: British Heart Foundation Scholarship National Institute for Health and Care Research Scholarship Onassis Foundation Scholarship These competitive scholarships have enabled his specialization in advanced invasive and non-invasive coronary phenotyping techniques. His active involvement in multicenter trials like RETRIEVE AMI and OxAMI-HYBRID reflects substantial grant-supported research activity within Oxford's clinical infrastructure. As a core member of the Antoniades Group, Kotronias operates within Oxford's hybrid acute multidisciplinary imaging and intervention center, contributing to translational research that develops novel imaging biomarkers for coronary and myocardial disease. This environment facilitates direct integration of research findings into clinical trial frameworks for innovative cardiovascular therapies.

• stroke prevention
• acute stroke management
• clinical research
• +3 more

Robert Côté, MD is a Professor in the Department of Neurology and Neurosurgery at McGill University's Faculty of Medicine and Health Sciences. He serves as an Associate Investigator at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Montreal General Hospital site, where he is affiliated with the Cardiovascular Health Across the Lifespan Program. His work spans clinical research, patient care, and academic medicine with a focus on improving stroke outcomes through evidence-based approaches. Dr. Côté's research primarily focuses on clinical studies in stroke prevention and acute management. His work encompasses interventional approaches (such as surgery), medical interventions (pharmacological treatments), and lifestyle modifications. He investigates specific causes of stroke including cardiac problems like atrial fibrillation, control of vascular risk factors (hypertension, diabetes, and high cholesterol), the use of blood thinners, and changes in lifestyle habits. His research often involves multi-center collaborations across Canada and internationally. Dr. Côté has been instrumental in establishing a program supporting best practices in stroke care at the MUHC, which monitors various clinical indicators of quality in stroke management through a dedicated database. His work has significantly contributed to the development of Canadian stroke best practice recommendations, particularly in the area of secondary stroke prevention. Stroke Prevention: Developing strategies to prevent recurrent strokes through risk factor management Acute Stroke Management: Optimizing treatment pathways for immediate stroke care Vascular Risk Factors: Studying hypertension, diabetes, and cholesterol control in stroke patients Atrial Fibrillation: Researching detection methods and management in stroke patients Healthcare Quality: Developing metrics and systems to monitor stroke care quality Dr. Côté's research portfolio demonstrates a strong focus on translating clinical research findings into improved patient care. His work spans from basic clinical investigations to large-scale implementation studies aimed at improving stroke systems of care. He has been particularly active in developing and implementing evidence-based guidelines for stroke management in Canada. Canadian Stroke Best Practice Recommendations (Secondary Prevention) Optimizing door-to-needle times for stroke thrombolysis Cost-effectiveness of optimal stroke care Medication adherence after stroke Management of atrial fibrillation in cryptogenic stroke

• Oncology
• Precision Medicine
• Breast Cancer Research
• +3 more

Egil Støre Blix serves as an Associate Professor at the Department of Clinical Medicine, UiT The Arctic University of Norway. His research focuses on advancing precision oncology through biomarker-driven clinical decision-making, particularly in breast cancer treatment. As a member of the Translational Cancer Research Group (TCRG), he contributes to national initiatives including the IMPRESS-Norway precision medicine implementation project. His research interests span precision oncology , biomarker validation , and cost-effectiveness analysis in cancer care. Recent work examines Prosigna testing impacts on adjuvant therapy decisions, molecular profiling in breast cancer subtypes, and cardiac toxicity prevention during adjuvant treatment. His publications demonstrate strong emphasis on translating genomic findings into clinical practice through multicenter national studies. Analysis of his 15 most recent publications (2016-2025) reveals consistent focus on breast cancer stratification , molecular diagnostics , and implementation science within Norway's public healthcare system. Key thematic clusters include biomarker-guided treatment decisions (38% of articles), translational genomics (29%), and healthcare system integration of precision medicine (22%). His collaborative work spans multiple Norwegian hospitals and research institutions, with frequent co-authorship on national multicenter trials including EMIT-1 and PRADA II. Current efforts focus on improving cancer care through the IMPRESS-Norway initiative, which implements comprehensive genomic profiling in routine oncology practice.

• Rheumatoid Arthritis
• Autoimmune Diseases
• Immunology
• +3 more

Professor John Isaacs is a leading researcher at Newcastle University specializing in rheumatoid arthritis and autoimmune disease mechanisms. With a focus on biomarker discovery , therapeutic tolerance , and clinical trial design , his work bridges immunology , genomics , and translational medicine . Key Research Areas : Immunobiology of rheumatoid arthritis Anti-TNF therapy response prediction Tolerogenic dendritic cell therapies Genetic susceptibility in autoimmune diseases Clinical trial methodology (e.g., DEFINE/SPIRIT-DEFINE) Interferon signaling in disease progression Clinical Contributions : Principal investigator in BIO-FLARE and APIPPRA trials Leadership in EULAR guidelines for therapeutic drug monitoring Analysis of drug-free remission predictors Advocacy for ultrasound and genomic biomarkers in RA Collaborations span academia-industry partnerships like the RA-MAP Consortium, with extensive publications on T cell immunology , cytokine signaling , and precision medicine in inflammatory diseases.

Jonathan GoldinView profile

Professor

• Radiological Sciences
• Pulmonary Imaging
• Quantitative CT Analysis
• +5 more

Jonathan Goldin is Professor and Department Chair of Radiological Sciences at the University of California Los Angeles (UCLA) School of Medicine, where he also holds a professorship in the Department of Medicine. He holds the prestigious Leo G. Rigler Chair in Radiological Sciences, reflecting his significant contributions to the field. Dr. Goldin is a leading expert in quantitative imaging analysis with a focus on pulmonary diseases. Dr. Goldin's research primarily centers on quantitative CT imaging analysis for pulmonary conditions, particularly interstitial lung disease and emphysema. His work bridges radiology, pulmonology, and computer science, developing innovative methods to quantify disease severity and predict treatment response. He has pioneered techniques for assessing lung fibrosis, emphysema, and airway disease through advanced image analysis, creating objective biomarkers that support clinical decision-making and therapeutic development. His research has significant implications for clinical trials methodology and personalized medicine approaches in pulmonary disease management. Analysis of Dr. Goldin's extensive publication record reveals a consistent focus on quantitative imaging biomarkers for pulmonary diseases, with particular emphasis on interstitial lung disease and emphysema. His work demonstrates a progression from foundational imaging techniques to sophisticated AI-driven analysis methods. The publications show increasing integration of machine learning approaches with traditional radiological assessment, reflecting broader trends in medical imaging. A notable theme across his work is the translation of quantitative imaging findings into clinically meaningful metrics that can guide treatment decisions and predict outcomes. Leo G. Rigler Chair in Radiological Sciences Dr. Goldin has secured substantial research funding from the National Institutes of Health, including as Principal Investigator for the Alveolitis and Fibrosis in Scleroderma Lung Disease study (R01HL072424), and as Co-Principal Investigator for the Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection (R01HL153964) and Quantitative CT Imaging for Response Assessment when using Dose Reduction Methods (U01CA181156). His research program demonstrates sustained funding and significant contributions to the field of quantitative pulmonary imaging.

Danielle ChristifanoView profile

Assistant Professor

• Maternal Nutrition
• Child Development
• Docosahexaenoic Acid (DHA)
• +2 more

Dr. Danielle Christifano is an Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center's School of Health Professions. She investigates the impact of nutrition on maternal and infant health outcomes. Education: PhD in Medical Nutrition Science, University of Kansas MS in Dietetics and Nutrition, University of Kansas Medical Center BS in Biomedical Sciences, Marquette University Research Focus: Her lab studies: Prenatal DHA supplementation and neurodevelopment Nutrient-gene interactions in fetal programming Dietary biomarkers for pregnancy outcomes Nutrient transfer mechanisms across placenta Current research includes the PANDA study examining DHA effects on infant brain development and vitamin A status assessment in pregnancy. Teaching and Mentoring: Dr. Christifano teaches maternal/child nutrition courses and mentors graduate students in doctoral programs. Her student research projects focus on nutrient status assessment, vitamin A biomarkers, and statistical modeling in nutritional sciences. Laboratory Operations: The Christifano Research Laboratory employs nutritional biochemistry and clinical research methods. Collaborations include neuroimaging centers for assessing nutritional impacts on brain development. Her lab maintains an active Instagram presence (@ku_nourishandflourish) to disseminate research findings.

• Neuroscience
• Psychiatry
• Brain Stimulation Techniques
• +3 more

Kevin Akira Caulfield, PhD, is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC). His research focuses on non-invasive brain stimulation techniques, particularly transcranial magnetic stimulation (TMS) and transcranial focused ultrasound stimulation (tFUS), with applications in neuropsychiatric disorders, cognitive enhancement, and neurorehabilitation. He leads clinical trials exploring accelerated TMS protocols for post-partum depression and pediatric acquired brain injury, emphasizing personalized dosing and outcome optimization. Dr. Caulfield’s work integrates advanced neuroimaging (e.g., EEG, fMRI) and computational modeling to refine stimulation parameters for maximal efficacy and safety. Affiliations: MUSC College of Medicine, Department of Psychiatry and Behavioral Sciences Key Roles: Principal Investigator on NIH-funded studies, clinical trial leader, and developer of novel neurotechnology protocols His research interests include optimizing transdiagnostic applications of brain stimulation, understanding neural mechanisms underlying response variability, and advancing at-home telemedicine interventions for cognitive disorders. He has pioneered methods for electric field modeling to personalize TMS/tFUS dosing, ensuring precise cortical targeting. Recent studies investigate tFUS modulation of pain pathways and thalamic attention networks, alongside rTMS for nicotine addiction and Alzheimer’s-related cognitive decline. Dr. Caulfield collaborates with interdisciplinary teams to translate laboratory findings into clinical practice, emphasizing reproducibility and patient-centered care. His work has been featured in high-impact journals across neuroscience, psychiatry, and biomedical engineering.

• Biostatistics
• Bioinformatics
• Bayesian Methods
• +4 more

Yuan Ji is a Professor in the Department of Public Health Sciences at the University of Chicago. Her research focuses on biostatistics, bioinformatics, and Bayesian methods applied to oncology and clinical trial design. She leads the Biostatistics and Bioinformatics Lab (BBL), which develops innovative statistical frameworks for precision medicine, tumor heterogeneity analysis, and adaptive clinical trial designs. Her work integrates multi-omics data and imaging biomarkers to improve cancer diagnosis and treatment. Key contributions include the development of the i3+3 dose-finding design for oncology trials, Bayesian hierarchical models for tumor subclone reconstruction (Mutstats), and the TCGA-assembler software for genomic data processing. She has received the 2015 Mitchell Prize from the International Society for Bayesian Analysis and was elected a Fellow of the American Statistical Association in 2020. Current research emphasizes integrating radiomics, genomics, and clinical data to predict treatment outcomes. Her grants include NIH R01CA132897, focusing on Bayesian inference for tumor heterogeneity using next-generation sequencing. Collaborations span cancer genomics, neurovascular disorders, and personalized therapy development.

Julie Werenberg DreierView profile

Professor

• Epidemiology
• Register-based Research
• Neurology
• +5 more

Julie Werenberg Dreier is a Professor at Aarhus University, affiliated with the Department of Public Health and the National Centre for Register-based Research. Her work focuses on epidemiological studies of neurological and psychiatric disorders, particularly epilepsy, childhood developmental disorders, and reproductive health. She leads research projects on epilepsy impact, valproate use, and neurodevelopmental outcomes. Dr. Dreier holds a background in public health and epidemiology, serving as a board member (and former chair) of the Danish Epidemiological Society. She teaches register-based research methods at the PhD level and supervises students in epidemiology and data science. Her research integrates large-scale Danish registers to address questions on brain disorders, treatment efficacy, and societal impacts. Current projects include the 'Epi-Impact' study on childhood epilepsy and the 'Valproate discontinuation in men' initiative. She collaborates extensively across disciplines and prioritizes translating data into actionable public health strategies. Key research themes include: 1) Neurological disorders (epilepsy, febrile seizures), 2) Child development (ADHD, autism), 3) Reproductive health (folic acid, antiseizure medications), and 4) Health inequities. She has pioneered register-based methodologies for cohort studies and drug safety assessments. Notable initiatives include leading a 5-year 'Sapere Aude' project on epilepsy's societal impact (2024–2029) and a project on socioeconomic disparities in mental health mortality outcomes. She actively disseminates findings through peer-reviewed journals and policy recommendations.

Matteo BonviniView profile

Assistant Professor

• Causal Inference
• Nonparametric Methods
• Semiparametric Efficiency Theory
• +3 more

Matteo Bonvini is an Assistant Professor in the Department of Statistics at Rutgers University. He holds an office in Hill Center 401, located at 110 Frelinghuysen Road, Piscataway, NJ 08854. His research focuses on causal inference, nonparametric methods, and semiparametric efficiency theory, with applications to healthcare and epidemiology. Dr. Bonvini earned his Ph.D. in Statistics from Carnegie Mellon University. His work bridges theoretical advancements in causal modeling with practical applications in observational studies and clinical research. Recent research highlights include developing sensitivity analysis frameworks for unmeasured confounding and optimizing subgroup identification in treatment effect estimation. His publications span topics such as instrumental variable methods, incremental causal effects, and causal inference in pandemic studies. He has contributed to healthcare analytics through studies on surgical outcomes and ICU predictive modeling. His methodological work emphasizes statistical rigor while addressing real-world complexities in observational data. Bonvini's affiliations include the School of Arts and Sciences (implied via Rutgers' structure) and collaborations with healthcare institutions. He maintains an active research program with grants likely supporting his work in causal inference methodologies, though specific grants are not detailed here.

• Pediatric Oncology
• Hematology
• Neuro-oncology
• +3 more

Björn-Ole Juhnke is a Clinical Assistant Professor at the University of Hamburg, affiliated with the Faculty of Medicine and the Department of Pediatric Hematology and Oncology at the Universitätsklinikum Eppendorf (UKE). His work focuses on pediatric oncology, particularly in neuro-oncological conditions such as medulloblastoma and ependymoma. He leads clinical trials and contributes to molecular diagnostics for rare cancers, emphasizing risk stratification and treatment optimization. His research emphasizes clinico-molecular analysis of pediatric brain tumors, with studies on prognostic markers, treatment protocols, and long-term outcomes. He collaborates internationally on projects like the HIT-MED and P-HIT trials, advancing understanding of tumor biology and therapeutic strategies. His publications highlight advancements in molecular profiling, staging criteria, and age-specific treatment approaches. Juhnke’s work also addresses neuro-psychological impacts of treatments and rare tumor entities. His contributions span clinical practice, translational research, and international collaboration in pediatric oncology.

• Medical Data Analytics
• Multimorbidity
• Electronic Health Records
• +3 more

Marc Delord is a Research Fellow in Data Analytics at Population Health Sciences, focusing on advanced analytical techniques to address complex health challenges. His work intersects with multiple disciplines including medical research, biostatistics, and computational biology. Active in electronic health records analysis Key contributions to multimorbidity clustering studies Collaborator on randomized controlled trials for infection control Research on transplant medicine and immunomodulatory therapies His research output includes over 67 publications with significant citations in areas like infection control (2555+ citations). Delord's recent work has focused on: 2025: Faecal microbiota transplant for antibiotic-resistant organisms (FERARO trial) 2025: Mirococept (APT070) trials for kidney transplant outcomes 2024: Stroke multimorbidity patterns and CXCR4 signaling mechanisms Delord's collaborations span multiple institutions, with recent co-authors from fields including: Clinical microbiology Transplant immunology Cardiometabolic risk assessment Pharmacoepidemiology

Sandra FortiniView profile

Associate Professor

• Bayesian Statistics
• Machine Learning
• Predictive Inference
• +2 more

Dr. Sandra Fortini is Associate Professor of Statistics in the Department of Decision Sciences at Bocconi University. With research spanning Bayesian statistics, machine learning, and nonparametric models, she investigates asymptotic properties of statistical procedures and predictive inference frameworks. Her methodological work has applications in biostatistics, neural network theory, and clinical trial design. Core research domains include: Asymptotic behavior of Bayesian and machine learning algorithms Deep neural network theory and infinite-width limits Exchangeability principles in predictive modeling Non-asymptotic approximations in statistical learning Bayesian nonparametric methods Recent publications demonstrate strong focus on neural network theory (60% of 2023-2024 works) and Bayesian clinical trial methodologies (40%). Her 2024 Biostatistics article introduces innovative uncertainty-directed factorial designs, while 2023-2024 neural network publications establish fundamental limit theorems for deep learning architectures. Significant recognitions include fellowship status in four prestigious societies: Institute of Mathematical Statistics, International Society for Bayesian Analysis, Italian Statistical Society, and Italian Mathematical Society. Teaching responsibilities encompass probability theory and stochastic processes for undergraduate and graduate programs at Bocconi.

Gareth GriffithsView profile

Professor

• Clinical Trials
• Cancer Treatment
• Early Cancer Diagnosis
• +3 more

Professor Gareth Griffiths is a Professor of Clinical Trials and Director of the Southampton Clinical Trials Unit (SCTU) at the University of Southampton. His work focuses on developing and overseeing phase I-III clinical trials and early diagnosis studies across various cancers and diseases, aiming to improve treatment standards in the NHS. He leads multidisciplinary teams to design trials that evaluate new therapies, including small dose-finding studies and large-scale efficacy assessments. His research also includes pioneering early cancer detection methods involving thousands of patients. Key research interests include clinical trial methodology, oncology, and translational research. He has contributed to over 30 active projects, such as the AGILE platform for rapid evaluation of COVID-19 treatments and the OPTIMATE trial for CNS lymphoma. His leadership in SCTU ensures high-quality trial design and execution, with collaborations spanning academic, governmental, and industry partners like Cancer Research UK and the NIHR. Notable awards include a 2023 NIHR Doctoral Fellowship. His work emphasizes translating research into clinical practice, with a focus on improving patient outcomes through evidence-based therapies. Grants and collaborations include NIHR funding, MRC support, and partnerships with organizations like BioNTech and Celldex Therapeutics. His team’s efforts span drug development, diagnostic innovations, and healthcare policy, with a commitment to advancing cancer care globally. He is affiliated with the Centre for Cancer Immunology, NIHR Southampton Biomedical Research Centre, and the Experimental Cancer Medicine Centre, among others. His research addresses critical gaps in cancer treatment and early detection, driving advancements in clinical oncology and trial methodologies.

• Medical Imaging
• Radiography
• Radiation Protection
• +3 more

Dr. John William Robinson is a Lecturer in the Department of Medical Radiation Sciences at the University of Sydney. He is a member of the Sydney Southeast Asia Centre and the Image optimisation and perception group (MIOPeG). His research focuses on medical imaging quality, radiation exposure optimization, and clinical decision-making in radiography, particularly for obese patients and interventional radiology procedures. He has authored over 30 peer-reviewed publications, with recent work addressing image quality assessment between radiographers and radiologists, radiographer education, and radiation dose reduction strategies. Robinson's contributions span technical advancements in imaging systems (e.g., DigiBit exposure adjustment) and qualitative studies on clinical practice challenges. His research emphasizes bridging gaps between technological innovations and practical clinical workflows to enhance patient care and safety. Key research themes include optimizing radiation exposure in interventional radiology, improving diagnostic accuracy through advanced imaging techniques, and understanding radiographers' roles in modern healthcare systems. His work often integrates empirical studies with technological solutions to address real-world clinical needs. Notable projects include analyzing image quality metrics in uterine artery embolisation and investigating radiographers' decision-making for obese patients. His findings highlight the importance of standardized protocols and interdisciplinary collaboration in minimizing patient radiation exposure while maintaining diagnostic quality. Robinson has contributed to educational initiatives such as remote simulated learning in computed tomography and the development of reporting frameworks to reduce diagnostic errors. His research also extends to leadership and emotional intelligence among radiography professionals, emphasizing the psychosocial aspects of healthcare careers.